Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (42) 42
female (35) 35
index medicus (35) 35
male (34) 34
gastroenterology & hepatology (32) 32
middle aged (32) 32
adult (30) 30
gastroenterology and hepatology (24) 24
hepatitis b (21) 21
aged (20) 20
treatment outcome (17) 17
hepatitis (15) 15
interferon (15) 15
antiviral agents - therapeutic use (14) 14
therapy (14) 14
hepatitis b, chronic - drug therapy (11) 11
hepatitis c (10) 10
hepatitis c virus (10) 10
analysis (9) 9
cirrhosis (9) 9
genotype (9) 9
mortality (9) 9
prospective studies (9) 9
young adult (9) 9
care and treatment (8) 8
dosage and administration (8) 8
drug therapy (8) 8
lamivudine (8) 8
patients (8) 8
risk factors (8) 8
thailand - epidemiology (8) 8
aged, 80 and over (7) 7
clinical trials (7) 7
dna, viral - blood (7) 7
health aspects (7) 7
hepatitis b e antigen (7) 7
hepatitis c, chronic - drug therapy (7) 7
infection (7) 7
liver cirrhosis (7) 7
retrospective studies (7) 7
ribavirin (7) 7
adolescent (6) 6
antiviral agents - adverse effects (6) 6
chronic hepatitis b (6) 6
chronic infection (6) 6
follow-up studies (6) 6
genotypes (6) 6
hepacivirus - genetics (6) 6
liver (6) 6
management (6) 6
medical research (6) 6
medicine, experimental (6) 6
prognosis (6) 6
risk (6) 6
severity of illness index (6) 6
antigens (5) 5
antiviral agents (5) 5
deoxyribonucleic acid--dna (5) 5
disease progression (5) 5
dna (5) 5
drug therapy, combination (5) 5
efficacy (5) 5
genetic aspects (5) 5
hepatitis b virus (5) 5
hepatitis b virus - genetics (5) 5
hepatitis b, chronic - complications (5) 5
hepatology (5) 5
logistic models (5) 5
patient outcomes (5) 5
predictive value of tests (5) 5
research (5) 5
research article (5) 5
thailand (5) 5
alanine transaminase - blood (4) 4
antiviral agents - administration & dosage (4) 4
antiviral therapy (4) 4
cancer (4) 4
cohort studies (4) 4
double-blind method (4) 4
hcv (4) 4
hepatitis b, chronic - virology (4) 4
hepatitis c, chronic - complications (4) 4
incidence (4) 4
infections (4) 4
infectious diseases (4) 4
interferon-alpha - therapeutic use (4) 4
liver cancer (4) 4
liver cirrhosis - complications (4) 4
liver cirrhosis - etiology (4) 4
liver diseases (4) 4
natural-history (4) 4
seroconversion (4) 4
survival (4) 4
tenofovir (4) 4
time factors (4) 4
transcatheter arterial chemoembolization (4) 4
united-states (4) 4
viral-hepatitis (4) 4
virology (4) 4
virus diseases (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Tu1477 – Aggressive Dose Reduction of Tenofovir (300 Mg Every 48 Hours Vs Every 72 Hours) Does Not Result in Viral Breakthrough in Tenofovir Treated Chronic Hepatitis B Patients with Moderate Renal Impairment
by Poosanasuwansri, Karn and Chotiyaputta, Watcharasak and Tanwandee, Tawesak
Gastroenterology, ISSN 0016-5085, 05/2019, Volume 156, Issue 6, pp. S-1336 - S-1336
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Sa1047 Combination of HBsAg Level and Hepatitis B Viral Load at Week 12 is the Best Stopping Rule for Chronic Hepatitis B, HBeAg Positive Patients Treated With Peginterferon ALPHA-2A
by Phisalprapa, Pochamana and Tanwandee, Tawesak
Gastroenterology, ISSN 0016-5085, 2012, Volume 142, Issue 5, pp. S-954 - S-955
Gastroenterology and Hepatology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon‐based therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B
by Limothai, Umaporn and Chuaypen, Natthaya and Poovorawan, Kittiyod and Chotiyaputta, Watcharasak and Tanwandee, Tawesak and Poovorawan, Yong and Tangkijvanich, Pisit
Journal of Viral Hepatitis, ISSN 1352-0504, 12/2019, Volume 26, Issue 12, pp. 1481 - 1488
Serum hepatitis B virus (HBV) RNA has emerged as a novel biomarker of treatment response. This study aimed to investigate the role of this marker in predicting... 
chronic hepatitis B | stopping rule | virological response | cccDNA | entecavir | HBsAg | pegylated interferon | HBV RNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
by Kudo, Masatoshi and Han, Guohong and Finn, Richard S and Poon, Ronnie T.P and Blanc, Jean‐Frederic and Yan, Lunan and Yang, Jijin and Lu, Ligong and Tak, Won‐Young and Yu, Xiaoping and Lee, Joon‐Hyeok and Lin, Shi‐Ming and Wu, Changping and Tanwandee, Tawesak and Shao, Guoliang and Walters, Ian B and Dela Cruz, Christine and Poulart, Valerie and Wang, Jian‐Hua
Hepatology, ISSN 0270-9139, 11/2014, Volume 60, Issue 5, pp. 1697 - 1707
Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate‐stage hepatocellular carcinoma (HCC). Brivanib, a... 
ANGIOGENESIS | ALANINATE | TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION | DUAL INHIBITOR | FACTOR RECEPTOR-2 | SORAFENIB | GASTROENTEROLOGY & HEPATOLOGY | EXPRESSION | CONFIDENCE | ENDOTHELIAL GROWTH-FACTOR | KINASES | Triazines - pharmacology | Alanine - therapeutic use | Alanine - adverse effects | Double-Blind Method | Triazines - therapeutic use | Chemoembolization, Therapeutic | Humans | Middle Aged | Liver Neoplasms - drug therapy | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Young Adult | Alanine - analogs & derivatives | Carcinoma, Hepatocellular - drug therapy | Treatment Failure | Aged, 80 and over | Adult | Female | Triazines - adverse effects | Aged | Chemotherapy, Adjuvant | Alanine - pharmacology | Confidence intervals | Liver cancer | Chemotherapy | Drug therapy | Ovarian cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
by Liaw, Yun-Fan and Sung, Joseph J.Y and Chow, Wan Cheng and Farrell, Geoffrey and Lee, Cha-Ze and Yuen, Hon and Tanwandee, Tawesak and Tao, Qi-Min and Shue, Kelly and Keene, Oliver N and Dixon, Jonathan S and Gray, D. Fraser and Sabbat, Jan and Cirrhosis Asian Lamivudine Multice and Cirrhosis Asian Lamivudine Multicentre Study Group
The New England Journal of Medicine, ISSN 0028-4793, 10/2004, Volume 351, Issue 15, pp. 1521 - 1531
In this placebo-controlled trial of patients with chronic hepatitis B and advanced fibrosis or cirrhosis, lamivudine reduced the rate of disease progression.... 
PROGNOSTIC FACTORS | UNITED-STATES | SURVIVAL | MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | VIRUS | CIRRHOSIS | TERM FOLLOW-UP | E-ANTIGEN SEROCONVERSION | NATURAL COURSE | INTERFERON THERAPY | Carcinoma, Hepatocellular - mortality | Prospective Studies | Carcinoma, Hepatocellular - prevention & control | Humans | Middle Aged | Male | Liver Neoplasms - mortality | Lamivudine - adverse effects | Lamivudine - therapeutic use | Adult | Female | Liver Neoplasms - prevention & control | Severity of Illness Index | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Double-Blind Method | Antiviral Agents - therapeutic use | Disease Progression | Drug Resistance - genetics | Hepatitis B, Chronic - complications | Hepatitis B, Chronic - drug therapy | Antiviral Agents - adverse effects | Adolescent | Hepatitis B virus - genetics | Liver Cirrhosis - pathology | Aged | Mutation | Lamivudine | Care and treatment | Dosage and administration | Liver diseases | Hepatitis B | Hepatitis | Liver cancer | Liver cirrhosis | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open‐label study
by Liaw, Yun‐Fan and Raptopoulou‐Gigi, Maria and Cheinquer, Hugo and Sarin, Shiv Kumar and Tanwandee, Tawesak and Leung, Nancy and Peng, Cheng‐Yuan and Myers, Robert P and Brown, Robert S and Jeffers, Lennox and Tsai, Naoky and Bialkowska, Jolanta and Tang, Shijie and Beebe, Suzanne and Cooney, Elizabeth
Hepatology, ISSN 0270-9139, 07/2011, Volume 54, Issue 1, pp. 91 - 100
A randomized, open‐label comparative study of entecavir versus adefovir therapy was performed in subjects with chronic hepatitis B who had hepatic... 
LAMIVUDINE TREATMENT | MANAGEMENT | THERAPY | NAIVE PATIENTS | CIRRHOSIS | RESISTANCE | DIPIVOXIL | GASTROENTEROLOGY & HEPATOLOGY | Adenine - analogs & derivatives | Liver Failure - mortality | Organophosphonates - therapeutic use | Antiviral Agents - therapeutic use | Guanine - analogs & derivatives | Humans | Middle Aged | Drug Resistance, Viral | Organophosphonates - adverse effects | Male | Survival Rate | Treatment Outcome | DNA, Viral - blood | Dose-Response Relationship, Drug | Liver Failure - virology | Adenine - adverse effects | Hepatitis B, Chronic - drug therapy | Adenine - therapeutic use | Antiviral Agents - adverse effects | Hepatitis B virus - genetics | Lamivudine - therapeutic use | Female | Guanine - adverse effects | Guanine - therapeutic use | Hepatitis | Interferon | Liver cirrhosis | Mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Treatment of Chronic Hepatitis C in Special Populations
by Bunchorntavakul, Chalermrat and Tanwandee, Tawesak
Gastroenterology Clinics of North America, ISSN 0889-8553, 12/2015, Volume 44, Issue 4, pp. 883 - 900
The management of hepatitis C virus (HCV) infection in special populations is challenging. The efficacy and safety data of the currently approved all-oral... 
Decompensated cirrhosis | Chronic kidney disease | Treatment | HIV coinfection | Hepatitis C virus | Liver transplantation | LIVER-TRANSPLANTATION | HUMAN-IMMUNODEFICIENCY-VIRUS | HCV INFECTION | SUSTAINED VIROLOGICAL RESPONSE | TREATMENT-NAIVE | TREATMENT-EXPERIENCED PATIENTS | GENOTYPE 1 INFECTION | GASTROENTEROLOGY & HEPATOLOGY | VIRAL-HEPATITIS | DRUG-DRUG INTERACTIONS | SEVERE RENAL IMPAIRMENT | Liver Transplantation | Antiviral Agents - therapeutic use | Coinfection - drug therapy | Liver Cirrhosis - complications | Humans | Hepatitis C, Chronic - surgery | Combined Modality Therapy | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Liver Cirrhosis - virology | Kidney Failure, Chronic - virology | HIV Infections - complications | Kidney Failure, Chronic - complications | Drug Therapy, Combination
Journal Article
Details down arrow
8. Full Text Ten‐day high‐dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication
by Auesomwang, Chonticha and Maneerattanaporn, Monthira and Chey, William D and Kiratisin, Pattarachai and Leelakusolwong, Somchai and Tanwandee, Tawesak
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 11/2018, Volume 33, Issue 11, pp. 1822 - 1828
Background and Aim Eradication rates of Helicobacter pylori following standard triple therapy are declining worldwide, but high‐dose proton pump... 
Helicobacter pylori | proton pump inhibitors | dyspepsia | CONCOMITANT THERAPY | METAANALYSIS | MANAGEMENT | EFFICACY | CLARITHROMYCIN RESISTANCE | CYP2C19 | AMOXICILLIN | CONSENSUS REPORT | TRIAL | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Prospective Studies | Nausea - chemically induced | Humans | Middle Aged | Male | Helicobacter Infections | Nausea - epidemiology | Proton Pump Inhibitors - administration & dosage | Time Factors | Clarithromycin - administration & dosage | Gastritis - microbiology | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Drug Therapy, Combination | Dizziness - epidemiology | Lansoprazole - administration & dosage | Gastritis - drug therapy | Proton Pump Inhibitors - adverse effects | Clarithromycin - adverse effects | Dizziness - chemically induced | Treatment Outcome | Lansoprazole - adverse effects | Amoxicillin - adverse effects | Aged | Patient Compliance | Anti-Bacterial Agents - administration & dosage | Drug resistance in microorganisms | Urea | Care and treatment | Amoxicillin | Dosage and administration | Patient compliance | Side effects | Clarithromycin | Motivation | Compliance | Dyspepsia | Antibiotic resistance | Nausea | Metronidazole | Patients
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Validation of the prognostic models in acute-on-chronic liver failure precipitated by hepatic and extrahepatic insults
by Maipang, K and Potranun, P and Chainuvati, S and Nimanong, S and Chotiyaputta, W and Tanwandee, T and Charatcharoenwitthaya, P
PLOS ONE, ISSN 1932-6203, 07/2019, Volume 14, Issue 7, p. e0219516
Background Patients with acute-on-chronic liver failure (ACLF) precipitated by hepatic injury and extrahepatic insults had distinct clinical phenotypes, and... 
MORTALITY | SURVIVAL | CLIF-SOFA | SCORE | PACIFIC ASSOCIATION | INDICATORS | MULTIDISCIPLINARY SCIENCES | DISTINCT | CIRRHOTIC-PATIENTS | CRITICALLY-ILL PATIENTS | Liver failure | Care and treatment | Phenotype | Prognosis | Diagnosis | Research | Risk factors | Phenotypes | Liver diseases | Laboratories | Syngeneic grafts | Liver | Mortality | Infections | Transplantation | Patients | Bleeding | Consortia | Medicine | Survival analysis | Hepatitis | Allografts | Sodium | Etiology | Hepatology | Medical prognosis | Gastroenterology | Models | Risk management | Failure | Liver transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial
by Sriprayoon, Tassanee and Mahidol, Chulabhorn and Ungtrakul, Teerapat and Chun‐on, Pattra and Soonklang, Kamonwan and Pongpun, Wanvisa and Laohapand, Charlie and Dechma, Jiraporn and Pothijaroen, Charinthip and Auewarakul, Chirayu and Tanwandee, Tawesak
Hepatology Research, ISSN 1386-6346, 03/2017, Volume 47, Issue 3, pp. E161 - E168
Aim Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are considered among the most potent antiviral agents for the treatment of chronic hepatitis B... 
hepatitis B | safety profile | antiviral therapy | HBeAg seroconversion, efficacy | KIDNEY-DISEASE | HBEAG | FOLLOW-UP | efficacy | THERAPY | HBeAg seroconversion | NAIVE PATIENTS | ALAFENAMIDE | PHARMACOKINETICS | DISOPROXIL FUMARATE | RESISTANCE | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Tenofovir | Antigens | Control | Clinical trials | Hepatitis C virus | Hepatitis C | Drug therapy | Health aspects | Liver cirrhosis | Hepatitis B | Antiviral agents | Alanine | Hepatitis B surface antigen | Liver | Chronic infection | Malignancy | Seroconversion | Patients | Hepatitis B e antigen | Cirrhosis | Hepatitis | Antiviral activity | Alanine transaminase | Interferon | Deoxyribonucleic acid--DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Acute gastrointestinal bleeding in anticoagulated patients: Prevalence and predictors of significant endoscopic lesions and change of the management
by Nawarawong, Napaporn and Pongprasobchai, Supot and Tanwandee, Tawesak
Journal of the Medical Association of Thailand, ISSN 0125-2208, 04/2018, Volume 101, Issue 4, pp. S135 - S142
Gastrointestinal bleeding | Predictor | Outcome | Anticoagulant | Endoscopy
Journal Article
Details down arrow
12. Full Text Efficacy and safety of nortriptyline in functional dyspepsia in Asians: A randomized double‐blind placebo‐controlled trial
by Kaosombatwattana, Uayporn and Pongprasobchai, Supot and Limsrivilai, Julajak and Maneerattanaporn, Monthira and Leelakusolvong, Somchai and Tanwandee, Tawesak
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 02/2018, Volume 33, Issue 2, pp. 411 - 417
Background and Aim Current treatments of functional dyspepsia (FD) are unsatisfied. Tricyclic antidepressants alter visceral hypersensitivity and brain–gut... 
nortriptyline | tricyclic antidepressant | functional dyspepsia | safety | efficacy | AMITRIPTYLINE | GUIDELINES | ANTIDEPRESSANT MEDICATIONS | TRICYCLIC ANTIDEPRESSANTS | ESCITALOPRAM | LEEDS DYSPEPSIA | GASTROINTESTINAL DISORDERS | QUESTIONNAIRE | GASTROENTEROLOGY & HEPATOLOGY | BOWEL DISORDERS | POSTPRANDIAL SYMPTOMS | Dyspepsia - drug therapy | Humans | Middle Aged | Male | Treatment Outcome | Young Adult | Asian Continental Ancestry Group | Nortriptyline - administration & dosage | Nortriptyline - adverse effects | Antidepressive Agents, Tricyclic - adverse effects | Adult | Female | Aged | Antidepressive Agents, Tricyclic - administration & dosage | Nortriptyline | Medical research | Gastrointestinal agents | Dyspepsia | Analysis | Clinical trials | Medicine, Experimental | Motivation | Antidepressants | Hypersensitivity | Tricyclic antidepressants | Safety | Quality of life
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Tu1498 – Changing of Skeletal Muscle Index After Direct Acting Antivirals Treatment in Chronic Hepatitis C Infected Patients with Advanced Fibrosis
by CHAREESIL, CHANIN and Charatcharoenwitthaya, Phunchai and Nimanong, Supot and Tanwandee, Tawesak and Chainuvati, Siwaporn P and Korpraphong, Pornpim and Chotiyaputta, Watcharasak
Gastroenterology, ISSN 0016-5085, 05/2019, Volume 156, Issue 6, pp. S-1343 - S-1344
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Sa1494 - Impact of Antiviral Therapy on Chronic Hepatitis B Patients who had High Viral Load, Persistently Normal Alt, and Mild Liver Fibrosis
by Teerawattananon, Choochai and Nimanong, Supot and Chainuvati, Siwaporn P and Charatcharoenwitthaya, Phunchai and Tanwandee, Tawesak and Chotiyaputta, Watcharasak
Gastroenterology, ISSN 0016-5085, 05/2018, Volume 154, Issue 6, pp. S-1132 - S-1132
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Hepatitis C genotype 6:A concise review and response-guided therapy proposal
by Chalermrat Bunchorntavakul Disaya Chavalitdhamrong Tawesak Tanwandee
世界肝病学杂志：英文版（电子版）, ISSN 1948-5182, 2013, Volume 5, Issue 9, pp. 496 - 504
Hepatitis C genotype 6 is endemic in Southeast Asia[prevalence varies between 10%-60% among all hepatitis C virus(HCV) infection], as well as also sporadically... 
Pegylated | C | therapy | Genotype | Southeast | interferon | Epidemiology | Ribavirin | Hepatitis | Treatment | Response-guided | Asia | 6 | Southeast asia | Pegylated interferon | Hepatitis c | Response-guided therapy | Genotype 6 | Southeast Asia | Minireviews | Hepatitis C
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study
by Moreno, Christophe and Berg, Thomas and Tanwandee, Tawesak and Thongsawat, Satawat and Van Vlierberghe, Hans and Zeuzem, Stefan and Lenz, Oliver and Peeters, Monika and Sekar, Vanitha and De Smedt, Goedele
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 56, Issue 6, pp. 1247 - 1253
Background & Aims TMC435 is an investigational, once-daily, oral NS3/4A protease inhibitor currently in phase III development for the treatment of hepatitis C... 
Gastroenterology and Hepatology | Genotype | Antiviral | HCV | Monotherapy | TMC435 | Simeprevir | Hepatitis C - drug therapy | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Male | Sulfonamides - pharmacokinetics | Sulfonamides - therapeutic use | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Adolescent | Hepatitis C - virology | Sulfonamides - adverse effects | Adult | Female | Aged | Hepacivirus - classification | Heterocyclic Compounds, 3-Ring - pharmacokinetics | Medical research | Antiviral agents | Aspartate | Hepatitis | Protease inhibitors | Proteases | Electrocardiogram | Electrocardiography | Medicine, Experimental | Genetic aspects | Dosage and administration | Hepatitis C virus | Hepatitis C | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients
by Laohapand, Charlie and Arromdee, Emvalee and Tanwandee, Tawesak
Hepatology International, ISSN 1936-0533, 4/2015, Volume 9, Issue 2, pp. 202 - 208
Hepatitis B virus (HBV) infection is still prevalent in Asia, including Thailand. HBV can archive in hepatocytes for life and can reactivate after... 
Medicine & Public Health | Colorectal Surgery | Hepatology | Surgery | Rheumatoid arthritis | HBV reactivation | Chronic HBV | Methotrexate | Thailand | Hepatitis B | FULMINANT-HEPATITIS | VIRUS-INFECTION | NATURAL-HISTORY | ARTHRITIS | DISCONTINUATION | THERAPY | DISEASE | C VIRUS | GASTROENTEROLOGY & HEPATOLOGY | WITHDRAWAL | ANTIGEN | Spondylarthropathies - drug therapy | Cross-Sectional Studies | Humans | Middle Aged | Male | Methotrexate - therapeutic use | Hepatitis B virus - physiology | Hepatitis B Surface Antigens - blood | DNA, Viral - blood | Hepatitis B Antibodies - blood | Virus Activation - drug effects | Time Factors | Arthritis, Rheumatoid - drug therapy | Hepatitis B virus - genetics | Lupus Erythematosus, Systemic - drug therapy | Adult | Female | Hepatitis B, Chronic - blood | Aged | Viral Load - drug effects | Hepatitis B virus - immunology | Antirheumatic Agents - therapeutic use | Relapse | Dosage and administration | Drug therapy | Risk factors | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Genetic variation in the Vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter study
by Thanapirom, Kessarin and Suksawatamnuay, Sirinporn and Sukeepaisarnjareon, Wattana and Tanwandee, Tawesak and Charatcharoenwitthaya, Phunchai and Thongsawat, Satawat and Leerapun, Apinya and Piratvisuth, Teerha and Boonsirichan, Rattana and Bunchorntavakul, Chalermrat and Pattanasirigool, Chaowalit and Pornthisarn, Bubpha and Tantipanichtheerakul, Supot and Sripariwuth, Ekawee and Jeamsripong, Woramon and Sanpajit, Teeranan and Poovorawan, Yong and Komolmit, Piyawat
PLoS ONE, ISSN 1932-6203, 03/2017, Volume 12, Issue 3, p. e0173263
Evidence of a role of vitamin D in the immune system is increasing. Low serum vitamin D is associated with increased hepatitis B virus replication. Genome-wide... 
LAMIVUDINE | THERAPY | POLYMORPHISMS | PEGINTERFERON ALPHA-2A | VIRUS INFECTION | ANALOGS | MULTIDISCIPLINARY SCIENCES | RIBAVIRIN | T-CELLS | GENOME-WIDE ASSOCIATION | Hepatitis B e Antigens - immunology | Recombinant Proteins - therapeutic use | Hepatitis B, Chronic - drug therapy | Cholestanetriol 26-Monooxygenase - genetics | Humans | Interferon-alpha - therapeutic use | Cytochrome P450 Family 2 - genetics | Polyethylene Glycols - therapeutic use | Hepatitis B Core Antigens - immunology | Care and treatment | Peginterferon alfa-2a | Vitamin D | Genetic variation | Analysis | Calcifediol | Dosage and administration | Alfacalcidol | Research | Hepatitis B | Therapy | Genes | 7-Dehydrocholesterol reductase | Chronic infection | Viruses | Infections | Genomes | Single-nucleotide polymorphism | Multivariate analysis | D gene | Hepatitis | α-Interferon | Hepatology | Gastroenterology | Pretreatment | Hepatitis B virus | Deoxyribonucleic acid--DNA | Genotypes | Immune system | Antigens | Immune response | Internal medicine | Vitamin deficiency | Genetic diversity | Patients | Seroconversion | Medicine | Hepatitis B e antigen | Hospitals | Interferon | Vitamin D receptors | Polymorphism | Deoxyribonucleic acid | DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights